Track topics on Twitter Track topics that are important to you
DelveInsight Psoriasis Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Psoriasis in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Psoriasis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Psoriasis. The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse Forecast model analysis by DelveInsight team of industry experts.
Please note: This report requires 57 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.
Scope of the Report
The Report includes the prevalent population and how will it change over the next eight years.
Prevalent or incident cases segmented by age and sex.
Coverage of key Psoriasis subpopulations and its prevalent or incident cases
The key differences in epidemiology patterns across the seven market segments
Key Coverage and Benefits
The report will help in developing business strategies by understanding the trends shaping and driving the global Psoriasis market.
Identifying prevalent patient populations as well as risk factors in the global Psoriasis market will help to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Psoriasis therapeutics in each of the markets covered.
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...